- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04814485
Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
A Prospective, Single-center Clinical Study to Explore the Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This trial is a prospective, single-center, single-arm clinical research. Advanced pancreatic cancer is an aggressive disease with extremely low 5-year survival rate. For advanced pancreatic cancer patients who failed with first-line treatment, subsequent treatment options are limited. SHR-1020 combined with albumin-bound paclitaxel could through multiple mechanisms such as block tumor mitosis, inhibit tumor angiogenesis, inhibit interstitial fibrosis to achieve anti-tumor effect.
The safety and efficacy of this study will be assessed through ORR, DCR,PFS, OS , and adverse effects as graded by CTCAE 5.0.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Rekrutierung
- Tianjin Medical University Cancer Institute and Hospital
-
Kontakt:
- jihui Hao, MD
- Telefonnummer: 022-23524155
- E-Mail: ec_tjcih@126.com
-
Kontakt:
- chuntao Gao, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients who were diagnosed as metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma by histopathology or cytology, at least one measurable lesion conforming to RECIST 1.1 criteria.
- Disease progresses or intolerance for first-line standard treatment, including patients who relapsed or metastasized within 6 months of neoadjuvant or adjuvant therapy
- ECOG score 0-2
- Adequate organ and bone marrow function
- The expected survival time is ≥ 12 weeks
- Had normal swallowing function, without dysfunction of gastrointestinal absorption
- Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures
Exclusion Criteria:
- The patient has previously received anti-angiogenic drugs or albumin-bound paclitaxel;
- The first study drug treatment was less than 2 weeks or 5 half-lives (in terms of longer) from the last chemotherapy or 5 half-lives from the last targeted therapy
- Known to be allergic to the active ingredients or excipients in this study.
- Had other active malignant tumors within 5 years before entering the study.
- Subject with cerebral metastasis
- Have a clear history of serious and uncontrolled other disease or mental disorders;
- Other chemotherapy, targeted therapy, hormonotherapy, immunotherapy, radiotherapy or traditional Chinese medicine should be used for anti-tumor therapy
- Other situations that the researcher considers inappropriate to participate in the research.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: SHR-1020 combined with albumin-bound paclitaxel
|
SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
ORR (Objective Response Rate)
Zeitfenster: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Containing the incidence of complete response (CR) and partial response (PR).
Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
DCR (Disease Control Rate)
Zeitfenster: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Containing the incidence of complete response (CR), partial response (PR) and stable disease (SD).Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
PFS (Progression-Free-Survival)
Zeitfenster: From date of treatment start until the date of progression or the date of death due to any caus, assessed up to 12 months
|
From date of treatment start until the date of progression or the date of death due to any cause.Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of treatment start until the date of progression or the date of death due to any caus, assessed up to 12 months
|
6mPFS
Zeitfenster: Up to 6 months
|
6-month- Progression-Free-Survival rate.
Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
Up to 6 months
|
OS (overall survival)
Zeitfenster: From date of treatment start until the date of death from any cause or censored at the last day that the patient is documented to be alive, whichever came first, assessed up to 12 months
|
From date of treatment start to any cause death or last follow-up.
|
From date of treatment start until the date of death from any cause or censored at the last day that the patient is documented to be alive, whichever came first, assessed up to 12 months
|
Adverse events (per CTCAE v5.0 criteria)
Zeitfenster: Up to 12months
|
To evaluate the adverse events of patients with advanced pancreatic cancer after treated with SHR-1020 plus albumin-bound paclitaxel
|
Up to 12months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen
- Neubildungen nach Standort
- Erkrankungen des endokrinen Systems
- Neoplasmen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neoplasmen der Bauchspeicheldrüse
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, Phytogen
- Paclitaxel
- Albumingebundenes Paclitaxel
Andere Studien-ID-Nummern
- PANC-2nd-IIT-FMTN-naP
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur SHR-1020+albumin-bound paclitaxel
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.RekrutierungSarkomatoides Karzinom der LungeChina
-
Jiangsu HengRui Medicine Co., Ltd.Noch keine Rekrutierung
-
Tianjin Medical University Cancer Institute and...Noch keine RekrutierungPlattenepithelkarzinom des Ösophagus | Progression zum PD-1-AntikörperChina
-
Jiangsu HengRui Medicine Co., Ltd.Rekrutierung
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... und andere MitarbeiterNoch keine RekrutierungGebärmutterhalskrebs | Lokal fortgeschrittener Gebärmutterhalskrebs | PD-L1-negativ | Neoadjuvante ChemoimmuntherapieChina
-
Xuanwu Hospital, BeijingUnbekanntNicht-kleinzelligem Lungenkrebs | PD-1-Antikörper | Lungenkrebs Stadium II
-
Jiangsu HengRui Medicine Co., Ltd.Aktiv, nicht rekrutierendNasopharynxkarzinomChina
-
China Medical University, ChinaUnbekanntFortgeschrittener MagenkrebsChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, nicht rekrutierendRezidivierendes Mammakarzinom | Brustkrebs im Stadium IV AJCC v6 und v7 | Brustkrebs im Stadium III AJCC v7 | Brustkrebs im Stadium IIIA AJCC v7 | Brustkrebs im Stadium IIIB AJCC v7 | Brustkrebs im Stadium IIIC AJCC v7 | Metastasierendes Mammakarzinom | Lokal fortgeschrittenes MammakarzinomVereinigte Staaten
-
Jiangsu HengRui Medicine Co., Ltd.AbgeschlossenBauchspeicheldrüsenkrebsChina